Bruker Corporation (NasdaqGS:BRKR) acquired 97.15% stake in Biognosys AG for CHF 75 million on January 3, 2023. The purchase price of CHF 75 million includes assumed liability for employee awards of CHF 5.9 million. Several of Biognosys? earlier investors have sold their shares to Bruker in a secondary transaction, and Bruker will make new primary investments in Biognosys. In connection with the acquisition, Bruker issued and sold stock in Biognosys to the two founding shareholders representing a 2.8% ownership interest in Biognosys. J.P. Morgan Securities LLC acted as financial advisor to Biognosys.

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition 97.15% stake in Biognosys AG on January 3, 2023.